Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).

Carvelli J, Meziani F, Dellamonica J, Cordier PY, Allardet-Servent J, Fraisse M, Velly L, Barbar SD, Lehingue S, Guervilly C, Desgrouas M, Camou F, Piperoglou C, Vely F, Demaria O, Karakunnel J, Fares J, Batista L, Rotolo F, Viotti J, Boyer-Chammard A, Lacombe K, Le Dault E, Carles M, Schleinitz N, Vivier E, FOR COVID Elimination (FORCE) Study Group

Open source

DOI: 10.1097/ccm.0000000000005683
Published: 2022 Dec 1
Container: Critical care medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/ccm.0000000000005683,
  title = {Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).},
  author = {Carvelli J and Meziani F and Dellamonica J and Cordier PY and Allardet-Servent J and Fraisse M and Velly L and Barbar SD and Lehingue S and Guervilly C and Desgrouas M and Camou F and Piperoglou C and Vely F and Demaria O and Karakunnel J and Fares J and Batista L and Rotolo F and Viotti J and Boyer-Chammard A and Lacombe K and Le Dault E and Carles M and Schleinitz N and Vivier E and FOR COVID Elimination (FORCE) Study Group},
  year = {2022},
  journal = {Critical care medicine},
  doi = {10.1097/ccm.0000000000005683},
  url = {https://doi.org/10.1097/ccm.0000000000005683}
}

RIS

TY  - JOUR
TI  - Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).
AU  - Carvelli J
AU  - Meziani F
AU  - Dellamonica J
AU  - Cordier PY
AU  - Allardet-Servent J
AU  - Fraisse M
AU  - Velly L
AU  - Barbar SD
AU  - Lehingue S
AU  - Guervilly C
AU  - Desgrouas M
AU  - Camou F
AU  - Piperoglou C
AU  - Vely F
AU  - Demaria O
AU  - Karakunnel J
AU  - Fares J
AU  - Batista L
AU  - Rotolo F
AU  - Viotti J
AU  - Boyer-Chammard A
AU  - Lacombe K
AU  - Le Dault E
AU  - Carles M
AU  - Schleinitz N
AU  - Vivier E
AU  - FOR COVID Elimination (FORCE) Study Group
PY  - 2022
JO  - Critical care medicine
DO  - 10.1097/ccm.0000000000005683
UR  - https://doi.org/10.1097/ccm.0000000000005683
ER  -

APA

J, C., F, M., J, D., PY, C., J, A., M, F., L, V., SD, B., S, L., C, G., M, D., F, C., C, P., F, V., O, D., J, K., J, F., L, B., F, R., J, V., A, B., K, L., E, L. D., M, C., N, S., E, V., & Group, F. C. E. (. S. (2022). Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).. Critical care medicine. https://doi.org/10.1097/ccm.0000000000005683

Source records

pubmed · retrieved 2026-09-26T23:17:41.225Z